2021
Relation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients With Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry)
Pareek M, Singh A, Vadlamani L, Eder M, Pacor J, Park J, Ghazizadeh Z, Heard A, Cruz-Solbes AS, Nikooie R, Gier C, Ahmed ZV, Freeman JV, Meadows J, Smolderen KGE, Lampert R, Velazquez EJ, Ahmad T, Desai NR. Relation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients With Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry). The American Journal Of Cardiology 2021, 146: 99-106. PMID: 33539857, PMCID: PMC7849530, DOI: 10.1016/j.amjcard.2021.01.029.Peer-Reviewed Original ResearchConceptsCardiovascular risk factorsCoronavirus disease 2019Risk factorsHigher troponin TCardiovascular diseaseCardiovascular eventsHospitalized patientsLaboratory findingsMental statusDisease 2019Multivariable binary logistic regression analysisTroponin TMajor adverse cardiovascular eventsPre-existing cardiovascular diseaseHigher C-reactive proteinCOVID-19 positive patientsPredictors of MACEPrevious ventricular arrhythmiaUse of P2YAdverse cardiovascular eventsProspective cohort studyTertiary care centerC-reactive proteinBinary logistic regression analysisPoor prognostic marker
2019
Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation
Loring Z, Shrader P, Allen LA, Blanco R, Chan PS, Ezekowitz MD, Fonarow GC, Freeman JV, Gersh BJ, Mahaffey KW, Naccarelli GV, Pieper K, Reiffel JA, Singer DE, Steinberg BA, Thomas LE, Peterson ED, Piccini JP. Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. American Heart Journal 2019, 219: 21-30. PMID: 31710841, PMCID: PMC7285625, DOI: 10.1016/j.ahj.2019.10.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAtrial FibrillationCardiovascular DiseasesCause of DeathComorbidityCoronary Artery DiseaseDiabetes MellitusDisease ProgressionEmbolismFemaleGuideline AdherenceHeart FailureHumansHyperlipidemiasHypertensionIntracranial EmbolismMalePeripheral Nervous System DiseasesPeripheral Vascular DiseasesRegistriesSleep Apnea, ObstructiveTreatment OutcomeConceptsGuideline-directed therapyAtrial fibrillationCause mortalityHeart failureAF progressionLower riskNew-onset heart failureObstructive sleep apnea patientsCox proportional hazards modelBetter Informed TreatmentObstructive sleep apneaSleep apnea patientsProportional hazards modelAF patientsDiabetes mellitusNeurovascular eventsClinical outcomesOutcomes RegistrySleep apneaApnea patientsComorbiditiesHazards modelNonsignificant trendPatientsLower mortalityTreatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II
Inohara T, Shrader P, Pieper K, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Go AS, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Mahaffey KW, Singer DE, Freeman JV, Steinberg BA, Peterson ED, Piccini JP, Patients and Investigators O. Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. American Heart Journal 2019, 213: 81-90. PMID: 31129441, DOI: 10.1016/j.ahj.2019.04.007.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsAtrial FibrillationCardiovascular DiseasesCoronary Artery DiseaseDrug Therapy, CombinationFactor Xa InhibitorsFemaleHemorrhageHumansMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationPeripheral Arterial DiseasePlatelet Aggregation InhibitorsProportional Hazards ModelsProspective StudiesRegistriesStrokeTreatment OutcomeWarfarinConceptsNew-onset atrial fibrillationDirect oral anticoagulantsConcomitant antiplatelet therapyPeripheral artery diseaseAtrial fibrillationVascular diseaseAntiplatelet therapyMajor bleedingArtery diseaseMyocardial infarctionORBIT-AF II registryAtrial Fibrillation IIImproved cardiovascular outcomesVascular disease patientsProportional hazards modelOutcomes of individualsOral anticoagulationCardiovascular outcomesOral anticoagulantsTriple therapyMost patientsPatient characteristicsCoronary diseaseDual therapyNeurological events
2018
B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation
Inohara T, Kim S, Pieper K, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Mahaffey KW, Singer DE, Freeman JV, Steinberg BA, Peterson ED, Piccini JP. B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. Heart 2018, 105: 370. PMID: 30228248, DOI: 10.1136/heartjnl-2018-313642.Peer-Reviewed Original ResearchConceptsB-type natriuretic peptideAtrial fibrillationAF progressionBNP levelsMajor bleedingBNP valuesNatriuretic peptideDisease progressionAtrial Fibrillation II registryBiomarker-based risk stratificationElevated BNP valuesBetter Informed TreatmentPersistent atrial fibrillationCox frailty modelCardiovascular outcomesComposite outcomeBNP concentrationsNeurological eventsClinical outcomesOutcomes RegistryRisk stratificationPatient outcomesInformed TreatmentPatientsBleeding
2015
Remote Monitoring and Outcomes in Pacemaker and Defibrillator Patients Big Data Saving Lives?∗
Freeman JV, Saxon L. Remote Monitoring and Outcomes in Pacemaker and Defibrillator Patients Big Data Saving Lives?∗. Journal Of The American College Of Cardiology 2015, 65: 2611-2613. PMID: 25983010, DOI: 10.1016/j.jacc.2015.04.031.Peer-Reviewed Original ResearchImpact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation—Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Holmqvist F, Guan N, Zhu Z, Kowey PR, Allen LA, Fonarow GC, Hylek EM, Mahaffey KW, Freeman JV, Chang P, Holmes DN, Peterson ED, Piccini JP, Gersh BJ, Investigators O. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation—Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal 2015, 169: 647-654.e2. PMID: 25965712, DOI: 10.1016/j.ahj.2014.12.024.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaBetter Informed TreatmentAtrial fibrillationOutcomes RegistrySleep apneaHigh riskStroke/transient ischemic attackContinuous positive airway pressure (CPAP) treatmentContinuous positive airway pressure therapyPrevalence of OSAInformed TreatmentImpact of OSAPositive airway pressure therapyPositive airway pressure treatmentAF progression rateHierarchical logistic regression modelingMajor cardiovascular outcomesRhythm control therapyAirway pressure therapyTransient ischemic attackLong-term outcomesRisk of deathLogistic regression modelingMore persistent formsCV death
2013
Use of Evidence-based Cardiac Prevention Therapy Among Outpatients with Atrial Fibrillation
Hess PL, Kim S, Piccini JP, Allen LA, Ansell JE, Chang P, Freeman JV, Gersh BJ, Kowey PR, Mahaffey KW, Thomas L, Peterson ED, Fonarow GC. Use of Evidence-based Cardiac Prevention Therapy Among Outpatients with Atrial Fibrillation. The American Journal Of Medicine 2013, 126: 625-632.e1. PMID: 23787195, PMCID: PMC4037289, DOI: 10.1016/j.amjmed.2013.01.037.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntihypertensive AgentsAtrial FibrillationCardiovascular DiseasesComorbidityDefibrillators, ImplantableEvidence-Based PracticeFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLogistic ModelsMalePlatelet Aggregation InhibitorsPractice Guidelines as TopicRegistriesRisk FactorsConceptsCardiovascular comorbid conditionsEvidence-based therapiesAtrial fibrillationRisk factorsComorbid conditionsEvidence-based therapy useMore evidence-based therapiesGuideline-recommended therapiesAngiotensin receptor blockersAntiarrhythmic drug therapyCardiovascular risk factorsPeripheral vascular diseaseMinority of patientsCoronary artery diseaseMultivariable logistic regressionUS national registryAngiotensin-converting enzymeAldosterone antagonistsComorbid illnessesReceptor blockersComorbid diseasesAntiplatelet agentsArtery diseaseDiabetes mellitusHeart failure
2009
The ageing athlete: screening prior to vigorous exertion in asymptomatic adults without known cardiovascular disease
Freeman J, Froelicher V, Ashley E. The ageing athlete: screening prior to vigorous exertion in asymptomatic adults without known cardiovascular disease. British Journal Of Sports Medicine 2009, 43: 696. PMID: 19734505, DOI: 10.1136/bjsm.2008.054783.Peer-Reviewed Original ResearchConceptsExercise ECG testingVigorous exercise programRisk factorsObservational studyECG testingCV eventsAsymptomatic patientsAsymptomatic menAsymptomatic adultsExercise programPrognostic valueExercise electrocardiogramCardiovascular diseaseMore CV risk factorsMultiple cardiac risk factorsAsymptomatic healthy womenIncident CV eventsCardiac risk factorsCV risk factorsProspective observational studySimilar prognostic valueExercise ECG testMore conclusive dataRisk factor exposureElderly patients
2008
Prediction of Cardiovascular Death using a Novel Heart Rate Recovery Parameter
HADLEY DM, DEWEY FE, FREEMAN JV, MYERS JN, FROELICHER VF. Prediction of Cardiovascular Death using a Novel Heart Rate Recovery Parameter. Medicine & Science In Sports & Exercise 2008, 40: 1072-1079. PMID: 18460999, DOI: 10.1249/mss.0b013e318167665a.Peer-Reviewed Original ResearchConceptsDuke treadmill scoreHeart rate recoveryHR increaseCV mortalityVagal toneCardiovascular causesCardiovascular deathPeak exerciseLowest tertileTreadmill scoreCox analysisClinical parametersMaximal exerciseSympathetic influencesExercise indexRate recoveryVagal influencePrognostic measurementMortalityPatientsRecovery variablesNormal scoresScoresExerciseRecovery parameters